367 related articles for article (PubMed ID: 36231529)
1. Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients.
Ordoñez-Vázquez AL; Juárez-Hernández E; Zuarth-Vázquez JM; Ramos-Ostos MH; Uribe M; Castro-Narro G; López-Méndez I
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231529
[TBL] [Abstract][Full Text] [Related]
2. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
[TBL] [Abstract][Full Text] [Related]
4. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
[TBL] [Abstract][Full Text] [Related]
6. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
[TBL] [Abstract][Full Text] [Related]
7. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
[TBL] [Abstract][Full Text] [Related]
8. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
Johira Y; Nakahara T; Kinami T; Yamasaki S; Kosaka M; Shirane Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Ando Y; Kosaka Y; Kodama K; Uchikawa S; Fujino H; Ono A; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Hayes CN; Tsuge M; Imamura M; Aikata H; Oka S
BMC Gastroenterol; 2023 Jun; 23(1):222. PubMed ID: 37380950
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
10. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
[TBL] [Abstract][Full Text] [Related]
11. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
[TBL] [Abstract][Full Text] [Related]
12. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
Kemp W; Clayton-Chubb D; Majeed A; Glenister KM; Magliano DJ; Lubel J; Bourke L; Simmons D; Roberts SK
J Gastroenterol Hepatol; 2022 Feb; 37(2):395-403. PubMed ID: 34693553
[TBL] [Abstract][Full Text] [Related]
13. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
[TBL] [Abstract][Full Text] [Related]
14. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults.
Shi A; Deng J; Ma J; Yang L; Tantai X; Wang Q; Chang D; Wang J; Guo X; Lu X; Shi H
Obes Facts; 2023; 16(6):548-558. PubMed ID: 37640023
[TBL] [Abstract][Full Text] [Related]
18. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease.
Rispo A; Imperatore N; Guarino M; Tortora R; Alisi A; Cossiga V; Testa A; Ricciolino S; Fiorentino A; Morisco F
Liver Int; 2021 Apr; 41(4):788-798. PubMed ID: 33319459
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.
Zeng J; Qin L; Jin Q; Yang RX; Ning G; Su Q; Yang Z; Fan JG
Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):154-161. PubMed ID: 35153138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
